# Effect of novel metabotropic glutamate receptor 5 antagonist on gastroesophageal reflux in dogs during anaesthesia

**Authors:** A. Glovéus, C. Ekstrand, A. Flöhr, S. Viskjer, O. Höglund

PMC · DOI: 10.1111/jsap.70053 · The Journal of Small Animal Practice · 2025-11-18

## TL;DR

This study tested a new drug to prevent stomach acid from flowing into the esophagus in anesthetized dogs but found it was not significantly effective.

## Contribution

The study evaluates TT001, a novel metabotropic glutamate receptor 5 antagonist, for reducing gastroesophageal reflux in anesthetized dogs.

## Key findings

- Gastroesophageal reflux occurred in 45.4% of dogs regardless of drug administration.
- TT001 did not significantly reduce reflux incidence compared to placebo in either protocol.
- No significant difference was observed between treatment groups in both protocols.

## Abstract

Gastroesophageal reflux during anaesthesia is a common event occurring in dogs with the potential to cause oesophageal injury and aspiration pneumonia. The objective of the current study was to evaluate the effect of the novel metabotropic glutamate receptor 5 antagonist TT001 on gastroesophageal reflux during anaesthesia in dogs using two different protocols.

One hundred and nineteen client‐owned dogs were included and randomly assigned to receive test‐drug containing either active TT001 (n = 58) or placebo vehicle (n = 61). In protocol 1 (n = 77), test‐drug was administered shortly before induction and in protocol 2 (n = 42) test‐drug was administered 15 minutes before standardised pre‐anaesthetic drugs. Gastroesophageal reflux (pH <4) was measured and recorded using oesophageal pH‐metry throughout the duration of the anaesthesia.

Gastroesophageal reflux was registered in 45.4% of dogs, in protocol 1: 44.2%, and in protocol 2: 47.6%. No overall statistically significant difference between the dogs receiving active TT001 (group A, 48.3%) and placebo (group B, 42.6%) was observed, regardless of the protocol tested (protocol 1: group A: 47.4%, group B: 41.0%; protocol 2: group A: 50.0%, group B: 45.5%).

Administration of metabotropic glutamate receptor 5 antagonist TT001 as a single intravenous bolus injection before or after pre‐anaesthetic drugs has limited effect on the incidence of gastroesophageal reflux in anaesthetised dogs.

## Linked entities

- **Diseases:** gastroesophageal reflux (MONDO:0007186), aspiration pneumonia (MONDO:0000265)

## Full-text entities

- **Genes:** GRM5 (glutamate metabotropic receptor 5) [NCBI Gene 485146]
- **Diseases:** Gastroesophageal reflux (MESH:D005764), aspiration pneumonia (MESH:D011015), oesophageal injury (MESH:D000077277)
- **Chemicals:** TT001 (-)
- **Species:** Canis lupus familiaris (dog, subspecies) [taxon 9615]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12968505/full.md

## References

46 references — full list in the complete paper: https://tomesphere.com/paper/PMC12968505/full.md

---
Source: https://tomesphere.com/paper/PMC12968505